Back to Authors

Geda, Yonas E

0000-0003-1187-7230

Mayo Clinic

Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona, USA.

Citations 110

Association of neighborhood socioeconomic disadvantage and cognitive impairment
Vassilaki, Maria , Aakre, Jeremiah A. , Castillo, Anna , Wilson, Patrick M. , Kremers, Walter K. , Geda, Yonas E. , Alhurani, Rabe E., Graff‐Radford, Jonathan , Vemuri, Prashanthi , Lowe, Val J. , Petersen, Ronald C. , Vemuri, Prashanthi , Geda, Yonas E , Castillo, Anna M , Kremers, Walter K , Chamberlain, Alanna M. , Mielke, Michelle M. , Machulda, Mary M. , Jack, Clifford R. , Knopman, David S.

Alzheimer's & Dementia | June 6, 2022 | Volume: 19 | Issue: 3 | Pages: 761-770

10.1002/alz.12702 Get It

AbstractIntroductionWe investigated the association of the area deprivation index (ADI) with cognitive decline, mild cognitive impairment (MCI), and dementia in older adults (≥50 years old). ADI is a neighborhood socioeconomic disadvantage measure assessed at the census block group level.MethodsThe study included 4699 participants, initially without dementia, with available ADI values for 2015 and at least one study visit in 2008 through 2018. Using logistic regression and Cox proportional hazards models with age as the time scale, we assessed the odds for MCI and the risk for dementia, respectively.ResultsIn cognitively unimpaired (CU) adults at baseline, the risk for progression to dementia increased for every decile increase in the ADI state ranking (hazard ratio = 1.06, 95% confidence interval (1.01–1.11), P = .01). Higher ADI values were associated with subtly faster cognitive decline.DiscussionIn older CU adults, higher baseline neighborhood socioeconomic deprivation levels were associated with progression to dementia and slightly faster cognitive decline.Highlights The study used area deprivation index, a composite freely available neighborhood deprivation measure. Higher levels of neighborhood deprivation were associated with greater mild cognitive impairment odds. Higher neighborhood deprivation levels were associated with higher dementia risk.
Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging
Krell‐Roesch, Janina , Rakuša, Martin , Syrjanen, Jeremy A. , Harten, Argonde C. van , Lowe, Val J. , Jack, Clifford R. , Kremers, Walter K. , Petersen, Ronald C. , Vassilaki, Maria , Geda, Yonas E. , Geda, Yonas E , Jack, Clifford R , Kremers, Walter K , Knopman, David S. , Stokin, Gorazd B.

Alzheimer's & Dementia | February 10, 2022 | Volume: 19 | Issue: 10 | Pages: 4498-4506

10.1002/alz.12557 Get It

Abstract Introduction We examined the association between cerebrospinal fluid (CSF)‐derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms (NPS) in older non‐demented adults. Methods We included 784 persons (699 cognitively unimpaired, 85 with mild cognitive impairment) aged ≥ 50 years who underwent CSF amyloid beta (Aβ42), hyperphosphorylated tau 181 (p‐tau), and total tau (t‐tau) as well as NPS assessment using Beck Depression and Anxiety Inventories (BDI‐II, BAI), and Neuropsychiatric Inventory Questionnaire (NPI‐Q). Results Lower CSF Aβ42, and higher t‐tau/Aβ42 and p‐tau/Aβ42 ratios were associated with BDI‐II and BAI total scores, clinical depression (BDI‐II ≥ 13), and clinical anxiety (BAI ≥ 10), as well as NPI‐Q–assessed anxiety, apathy, and nighttime behavior. Discussion CSF Aβ42, t‐tau/Aβ42, and p‐tau/Aβ42 ratios were associated with NPS in community‐dwelling individuals free of dementia. If confirmed by a longitudinal cohort study, the findings have clinical relevance of taking into account the NPS status of individuals with abnormal CSF biomarkers.
Association of Performance on the Financial Capacity Instrument–Short Form With Brain Amyloid Load and Cortical Thickness in Older Adults
Vassilaki, Maria , Aakre, Jeremiah A. , Kremers, Walter K. , Mielke, Michelle M. , Geda, Yonas E. , Vemuri, Prashanthi , Lowe, Val J. , Jack, Clifford R. , Roberson, Erik D. , Gerstenecker, Adam , Martin, Roy C. , Kennedy, Richard , Marson, Daniel , Petersen, Ronald C. , Jack, Clifford R , Roberson, Erik , Kennedy, Richard E , Marson, Daniel C, Mielke, Michelle M , Vemuri, Prashanthi , Geda, Yonas E , Kremers, Walter K , Machulda, Mary M. , Knopman, David S.

Neurology Clinical Practice | February 8, 2022 | Volume: 12 | Issue: 2 | Pages: 113-124

10.1212/cpj.0000000000001157 Get It

Investigating cognition in midlife
Novotný, Jan , Medina‐Inojosa, José R. , Lopez‐Jimenez, Francisco, Geda, Yonas E. , Stokin, Gorazd B. , Medina-Inojosa, José R , Geda, Yonas E , Novotny, Jan S , González‐Rivas, Juan P. , López-Jiménez, Francisco

Alzheimer's & Dementia: Translational Research & Clinical Interventions | December 31, 2021 | Volume: 7 | Issue: 1 | Pages: No page available

10.1002/trc2.12234 Get It

Abstract We here posit that measurements of midlife cognition can be instructive in understanding cognitive disorders. Even though molecular events signal possible onset of cognitive disorders decades prior to their clinical diagnoses, cognition and its possible early changes in midlife remain poorly understood. We characterize midlife cognition in a cognitively healthy population‐based sample using the Cogstate Brief Battery and test for associations with cardiovascular, adiposity‐related, lifestyle‐associated, and psychosocial variables. Learning and working memory showed significant variability and vulnerability to psychosocial influences in midlife. Furthermore, midlife aging significantly and progressively increased prevalence of suboptimal cognitive performance. Our findings suggest that physiological changes in cognition, measured with simple tests suitable for use in everyday clinical setting, may signal already in midlife the first clinical manifestations of the presymptomatic biologically defined cognitive disorders. This pilot study calls for longitudinal studies investigating midlife cognition to identify clinical correlates of biologically defined cognitive disorders.
A longitudinal investigation of Aβ, anxiety, depression, and mild cognitive impairment
Pink, Anna , Syrjanen, Jeremy A. , Vassilaki, Maria , Lowe, Val J. , Vemuri, Prashanthi , Christianson, Teresa J., Kremers, Walter K. , Jack, Clifford R. , Petersen, Ronald C. , Geda, Yonas E. , Krell-Roesch, Janina, Geda, Yonas E , Jack, Clifford R , Vemuri, Prashanthi , Kremers, Walter K , Krell‐Roesch, Janina , Stokin, Gorazd B. , Knopman, David S.

Alzheimer's & Dementia | December 8, 2021 | Volume: 18 | Issue: 10 | Pages: 1824-1831

10.1002/alz.12504 Get It

Abstract Introduction We investigated the longitudinal relationship between cortical amyloid deposition, anxiety, and depression and the risk of incident mild cognitive impairment (MCI). Methods We followed 1440 community‐dwelling, cognitively unimpaired individuals aged ≥ 50 years for a median of 5.5 years. Clinical anxiety and depression were assessed using Beck Anxiety and Depression Inventories (BAI, BDI‐II). Cortical amyloid beta (Aβ) was measured by Pittsburgh compound B positron emission tomography (PiB‐PET) and elevated deposition (PiB+) was defined as standardized uptake value ratio ≥ 1.48. We calculated Cox proportional hazards models with age as the time scale, adjusted for sex, education, and medical comorbidity. Results Cortical Aβ deposition (PiB+) independent of anxiety (BAI ≥ 10) or depression (BDI‐II ≥ 13) increased the risk of MCI. There was a significant additive interaction between PiB+ and anxiety (joint effect hazard ratio 6.77; 95% confidence interval 3.58–12.79; P = .031) that is, being PiB+ and having anxiety further amplified the risk of MCI. Discussion Anxiety modified the association between PiB+ and incident MCI.
NIA‐AA Alzheimer's Disease Framework: Clinical Characterization of Stages
Petersen, Ronald C. , Wiste, Heather J. , Weigand, Stephen D. , Fields, Julie A. , Geda, Yonas E. , Graff‐Radford, Jonathan , Knopman, David S. , Kremers, Walter K. , Lowe, Val J. , Therneau, Terry M. , Vemuri, Prashanthi , Knopman, David S. , Mielke, Michelle M , Stricker, Nikki H. , Vemuri, Prashanthi , Geda, Yonas E , Kremers, Walter K , Machulda, Mary M. , Mielke, Michelle M. , Jack, Clifford R.

Annals of Neurology | March 27, 2021 | Volume: 89 | Issue: 6 | Pages: 1145-1156

10.1002/ana.26071 Get It

BackgroundTo operationalize the National Institute on Aging – Alzheimer's Association (NIA‐AA) Research Framework for Alzheimer's Disease 6‐stage continuum of clinical progression for persons with abnormal amyloid.MethodsThe Mayo Clinic Study of Aging is a population‐based longitudinal study of aging and cognitive impairment in Olmsted County, Minnesota. We evaluated persons without dementia having 3 consecutive clinical visits. Measures for cross‐sectional categories included objective cognitive impairment (OBJ) and function (FXN). Measures for change included subjective cognitive impairment (SCD), objective cognitive change (ΔOBJ), and new onset of neurobehavioral symptoms (ΔNBS). We calculated frequencies of the stages using different cutoff points and assessed stability of the stages over 15 months.ResultsAmong 243 abnormal amyloid participants, the frequencies of the stages varied with age: 66 to 90% were classified as stage 1 at age 50 but at age 80, 24 to 36% were stage 1, 32 to 47% were stage 2, 18 to 27% were stage 3, 1 to 3% were stage 4 to 6, and 3 to 9% were indeterminate. Most stage 2 participants were classified as stage 2 because of abnormal ΔOBJ only (44–59%), whereas 11 to 21% had SCD only, and 9 to 13% had ΔNBS only. Short‐term stability varied by stage and OBJ cutoff points but the most notable changes were seen in stage 2 with 38 to 63% remaining stable, 4 to 13% worsening, and 24 to 41% improving (moving to stage 1).InterpretationThe frequency of the stages varied by age and the precise membership fluctuated by the parameters used to define the stages. The staging framework may require revisions before it can be adopted for clinical trials. ANN NEUROL 2021;89:1145–1156
Neuropsychiatric symptoms and the outcome of cognitive trajectories in older adults free of dementia: The Mayo Clinic Study of Aging
Syrjanen, Jeremy A. , Christianson, Teresa J., Kremers, Walter K. , Petersen, Ronald C. , Vassilaki, Maria , Geda, Yonas E. , Krell-Roesch, Janina, Geda, Yonas E , Kremers, Walter K , Krell‐Roesch, Janina , Machulda, Mary M. , Mielke, Michelle M. , Knopman, David S.

International Journal of Geriatric Psychiatry | March 16, 2021 | Volume: 36 | Issue: 9 | Pages: 1362-1369

10.1002/gps.5528 Get It

Abstract Objective Neuropsychiatric symptoms (NPS) are associated with the risk of incident mild cognitive impairment (MCI) and dementia. We examined associations between NPS and the outcomes of global and domain‐specific cognitive trajectories. Methods In this longitudinal study conducted in the setting of the population‐based Mayo Clinic Study of Aging, 5081 community‐dwelling, nondemented individuals aged ≥50 years (51% males) underwent NPS assessment using Neuropsychiatric Inventory Questionnaire (NPI‐Q), and Beck Depression and Anxiety Inventories (BDI‐II, BAI). Global and domain‐specific (memory, language, attention, and visuospatial skills) cognitive performance was assessed through neuropsychological testing every 15 months. Associations between baseline NPS and trajectories for individual yearly change in cognitive z‐scores were calculated using linear mixed‐effect models. Results Cognition declined regardless of NPS status over the median follow‐up of 4.5 years. Presence of NPS was associated with increased cognitive decline. Differences in annualized change in global cognition z‐scores for participants with NPS compared to without NPS ranged from −0.018 (95% CI −0.032, −0.004; p = 0.011) for irritability to −0.159 (−0.254, −0.065; p = 0.001) for hallucinations. Associations between NPS and annual decline in global cognition were significant for most NPI‐Q‐assessed NPS and clinical depression (BDI‐II≥13). Participants with NPI‐Q‐assessed depression, apathy, nighttime behavior, and clinical depression had greater decline in all domain‐specific z‐scores; presence of delusions and anxiety was associated with more pronounced decline in language, attention and visuospatial skills. Conclusion NPS were associated with a more accelerated cognitive decline. Clinical assessment and potential treatment of NPS is warranted even in a community setting as NPS may impact cognitive decline in nondemented individuals.
Physical Activity and Trajectory of Cognitive Change in Older Persons: Mayo Clinic Study of Aging
Syrjanen, Jeremy A. , Bezold, Jelena, Trautwein, Sandra , Barisch‐Fritz, Bettina , Boes, Klaus, Wöll, Alexander , Forzani, Erica , Kremers, Walter K. , Petersen, Ronald C. , Vassilaki, Maria , Geda, Yonas E. , Krell-Roesch, Janina, Geda, Yonas E , Kremers, Walter K , Krell‐Roesch, Janina , Machulda, Mary M. , Mielke, Michelle M. , Knopman, David S.

Journal of Alzheimer's Disease | November 17, 2020 | Volume: 79 | Issue: 1 | Pages: 377-388

10.3233/jad-200959 Get It

Background: Little is known about the association between physical activity (PA) and cognitive trajectories in older adults. Objective: To examine the association between PA and change in memory, language, attention, visuospatial skills, and global cognition, and a potential impact of sex or Apolipoprotein E (APOE) ɛ4 status. Methods: Longitudinal study derived from the population-based Mayo Clinic Study of Aging, including 2,060 cognitively unimpaired males and females aged ≥70 years. Engagement in midlife (ages 50–65) and late-life (last year) PA was assessed using a questionnaire. Neuropsychological testing was done every 15 months (mean follow-up 5.8 years). We ran linear mixed-effect models to examine whether mid- or late-life PA at three intensities (mild, moderate, vigorous) was associated with cognitive z-scores. Results: Light intensity midlife PA was associated with less decline in memory function compared to the no-PA reference group (time x light PA; estimate [standard error] 0.047 [0.016], p = 0.004). Vigorous late-life PA was associated with less decline in language (0.033 [0.015], p = 0.030), attention (0.032 [0.017], p = 0.050), and global cognition (0.039 [0.016], p = 0.012). Females who were physically inactive in midlife experienced more pronounced cognitive decline than females physically active in midlife and males regardless of PA (p-values for time interaction terms with midlife PA levels and sex were all p < 0.05 for global cognition). APOE ɛ4 carriership did not moderate the association between PA and cognition. Conclusion: Engaging in PA, particularly of vigorous intensity in late-life, was associated with less pronounced decline in global and domain-specific cognition. This association may differ by sex.
Association of Cortical and Subcortical β-Amyloid With Standardized Measures of Depressive and Anxiety Symptoms in Adults Without Dementia
Syrjanen, Jeremy A. , Rakuša, Martin , Vemuri, Prashanthi , Kremers, Walter K. , Lowe, Val J. , Jack, Clifford R. , Stokin, Gorazd B. , Petersen, Ronald C. , Vassilaki, Maria , Geda, Yonas E. , Krell-Roesch, Janina, Jack, Clifford R , Vemuri, Prashanthi , Geda, Yonas E , Stokin, Gorazd , Kremers, Walter K , Krell‐Roesch, Janina , Machulda, Mary M. , Mielke, Michelle M. , Knopman, David S.

The Journal of Neuropsychiatry and Clinical Neurosciences | October 22, 2020 | Volume: 33 | Issue: 1 | Pages: 64-71

10.1176/appi.neuropsych.20050103 Get It